197 related articles for article (PubMed ID: 27222479)
1. Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
Cheson BD
Blood; 2016 Jul; 128(3):325-30. PubMed ID: 27222479
[TBL] [Abstract][Full Text] [Related]
2. Idelalisib, ibrutinib show benefits in CLL.
Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
[No Abstract] [Full Text] [Related]
3. In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.
Tarantelli C; Gaudio E; Cascione L; Stathis A; Zucca E; Bertoni F
Br J Haematol; 2019 Jul; 186(1):149-152. PubMed ID: 30569468
[No Abstract] [Full Text] [Related]
4. Targeting of B-cell receptor signalling in B-cell malignancies.
Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
[TBL] [Abstract][Full Text] [Related]
5. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
[TBL] [Abstract][Full Text] [Related]
6. Possible novel agents in marginal zone lymphoma.
Zinzani PL; Broccoli A
Best Pract Res Clin Haematol; 2017; 30(1-2):149-157. PubMed ID: 28288710
[TBL] [Abstract][Full Text] [Related]
7. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
[TBL] [Abstract][Full Text] [Related]
8. Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Maffei R; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
J Hematol Oncol; 2015 May; 8():60. PubMed ID: 26022368
[TBL] [Abstract][Full Text] [Related]
9. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
11. Current strategies to create tailored and risk-adapted therapies for CLL patients.
Cramer P; Eichhorst B; Reinhardt HC; Hallek M
Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
[TBL] [Abstract][Full Text] [Related]
12. Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
Mato AR; Samp JC; Gauthier G; Terasawa E; Brander DM
Cancer Biol Ther; 2018 Jul; 19(7):636-643. PubMed ID: 29584544
[TBL] [Abstract][Full Text] [Related]
13. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
Lamanna N
Oncology (Williston Park); 2015 Jun; 29(6):443, 445. PubMed ID: 26091680
[No Abstract] [Full Text] [Related]
14. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Rodgers TD; Reagan PM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323
[TBL] [Abstract][Full Text] [Related]
15. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Godet S; Protin C; Dupuis J; Dartigeas C; Bastie JN; Herbaux C; Leblond V; de Guibert S; Ghez D; Brion A; Ysebaert L; Delmer A; Quinquenel A
Am J Hematol; 2018 Feb; 93(2):E52-E54. PubMed ID: 29164674
[No Abstract] [Full Text] [Related]
16. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
Müschen M
Blood; 2015 Jun; 125(24):3688-93. PubMed ID: 25878119
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Waldron M; Winter A; Hill BT
Clin Pharmacokinet; 2017 Nov; 56(11):1255-1266. PubMed ID: 28343293
[TBL] [Abstract][Full Text] [Related]
18. B cell receptor inhibition as a target for CLL therapy.
Jeyakumar D; O'Brien S
Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
[TBL] [Abstract][Full Text] [Related]
19. Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.
Rhodes J; Mato A; Sharman JP
Curr Oncol Rep; 2018 Apr; 20(6):49. PubMed ID: 29644450
[TBL] [Abstract][Full Text] [Related]
20. Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.
Woyach JA
Hematology Am Soc Hematol Educ Program; 2015; 2015():355-60. PubMed ID: 26637743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]